GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q32 Bio Inc (STU:DB0) » Definitions » Additional Paid-In Capital

Q32 Bio (STU:DB0) Additional Paid-In Capital : €223.69 Mil(As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Q32 Bio Additional Paid-In Capital?


Q32 Bio's quarterly additional paid-in capital increased from Sep. 2024 (€215.27 Mil) to Dec. 2024 (€229.67 Mil) but then stayed the same from Dec. 2024 (€229.67 Mil) to Mar. 2025 (€223.69 Mil).

Q32 Bio's annual additional paid-in capital increased from Dec. 2022 (€2.48 Mil) to Dec. 2023 (€3.81 Mil) and increased from Dec. 2023 (€3.81 Mil) to Dec. 2024 (€229.67 Mil).


Q32 Bio Additional Paid-In Capital Historical Data

The historical data trend for Q32 Bio's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Q32 Bio Additional Paid-In Capital Chart

Q32 Bio Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Additional Paid-In Capital
1.17 2.48 3.81 229.67

Q32 Bio Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 216.04 219.75 215.27 229.67 223.69

Q32 Bio Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Q32 Bio Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Q32 Bio's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Q32 Bio Business Description

Industry
Traded in Other Exchanges
Address
830 Winter Street, Waltham, MA, USA, 02451
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

Q32 Bio Headlines

No Headlines